Ted Love. HAVERFORD COLLEGE
Global Blood Therapeutics poised to submit application for accelerated approval, with new pivotal data on its sickle cell disease drug
Global Blood Therapeutics is set to submit an application for accelerated approval in the second-half of this year, after unveiling fresh data from a late-stage trial that showed just over half the patients given the highest dose of its experimental sickle cell disease drug experienced a statistically significant improvement in oxygen-wielding hemoglobin, meeting the study’s main goal.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters